Register: From Clinical to Commercial: Talent Strategies for Biopharma Growth

ABOUT THE EVENT

Date: Wednesday, July 22, 2026 2–3pm EDT
Event Location: Virtual

Early indications in 2026 are pointing towards a slight recovery in the biopharma job market. Join industry hiring experts for a data-informed discussion on where the life sciences job market stands today, what trends we are witnessing in hiring and how hiring managers and HR and talent acquisition professionals can navigate shifts towards commercial readiness and/or building out commercial teams.

This webinar will provide a clear-eyed assessment of current hiring conditions across biopharma, exploring how the economic climate is impacting workforce development and how hiring practices are evolving as organizations prepare to take products to market.

Xiao Zhang
Head of Global Pipeline Commercialization and Strategy for Gastroenterology | AbbVie
Dr. Xiao Zhang is a clinician, scientist, and product commercialization leader whose entrepreneurial drive and marketing acumen are transforming the pharmaceutical industry. Xiao holds a Doctor of Pharmacy degree from Rutgers University and an MBA from Northwestern University Kellogg School of Management.
Michael Campbell
Chief Commercial Officer | Eyepoint
As Chief Commercial Officer, Michael (Mike) Campbell leads EyePoint’s commercial strategy and operations, leveraging over 30 years of commercial leadership experience, where he scaled global commercial organizations and pioneered patient-focused strategies for commercializing innovative ophthalmologic products. Prior to joining EyePoint, Mike was the Chief Commercial Officer at Opthea, where he built the commercial organization and led pre-launch readiness for a potential new product for the treatment of wet AMD. Prior to Opthea, he oversaw various commercial activities including ophthalmologic product launches, sales and marketing, and pre-launch activities across his roles as Senior Vice President and Head of Commercial at Viatris Eye Care, as Vice President of Biologic Commercialization in retina at Novartis, and as Vice President of the U.S. Ophthalmology Business Unit at Shire. Additionally, Mike held commercial leadership roles at Genentech, where he was a key leader in the commercial launch of Lucentis®. Mike also held various sales and commercial roles at Johnson & Johnson Vision Care, Eli Lilly, and AstraZeneca / Medimmune. He holds a Bachelor of Science degree from Auburn University and is an Executive Education graduate from the University of Pennsylvania, Wharton School of Business.
Margaret Blackwell
Head of Talent Acquisition, Strategic Consultative Partnerships | Amplity
Margaret Blackwell leads Amplity’s Direct Recruiting business and broader talent acquisition function, helping life sciences companies build the teams that power their success. She brings more than 25 years of experience in pharmaceutical talent acquisition, placing both teams and individual candidates across top 10 global pharma companies and emerging biotech firms.

Over her career, Margaret has built more than 155 teams—from oncology and specialized rare disease to nurse educator teams and large-scale specialty sales forces—enabling thousands of successful hires.

At Amplity, Margaret drives retained, high-impact recruiting solutions designed to deliver talent quicker, better, and with true partnership. Her team works seamlessly with business leaders, HR, and talent acquisition organizations, combining deep industry expertise with expansive networks to help clients hire, scale, and backfill with confidence. Through Amplity’s partnership-first, retainer-based model, they consistently deliver top-tier commercial and medical talent with precision and speed.

Chantal Dresner
Chantal Dresner
Vice President of Marketing

MORE EVENTS
FDA’s draft guidance on the validation of non-animal methods (NAMs) is reshaping how nonclinical programs are designed and justified. This webinar explores how sponsors can apply NAMs to streamline development, improve human relevance, and support IND decision-making within a weight-of-evidence framework.
Wednesday, July 1, 2026 10–11am EDT
 · 
Virtual